ZECEN provides quantitative thrombosis test kits designed to support the evaluation of coagulation activation, fibrinolytic activity, and vascular endothelial injury. Our diagnostic reagent range includes Thrombomodulin (TM), Tissue-type Plasminogen Activator-Inhibitor Complex (t-PAIC), Plasmin-α2-Plasmin Inhibitor Complex (PIC), and Thrombin-Antithrombin III Complex (TAT). These thrombosis-related biomarker assays provide valuable laboratory information for assessing suspected thrombotic conditions and coagulation abnormalities in hospitals and diagnostic centers.
Our clinical thrombosis detection reagents cover molecular markers associated with different stages and mechanisms of coagulation and fibrinolysis.
Coagulation Activation Marker (TAT): Thrombin-Antithrombin III Complex reflects thrombin generation and coagulation system activation, providing information relevant to hypercoagulable states.
Fibrinolytic System Markers (PIC and t-PAIC): PIC indicates plasmin generation and fibrinolytic activation, while t-PAIC provides information about fibrinolytic inhibition and related endothelial changes.
Vascular Endothelial Injury Marker (TM): Thrombomodulin is associated with vascular endothelial function, and elevated circulating levels may indicate endothelial injury.
ZECEN's specialized thrombosis biomarker test kits support clinical investigations involving thrombotic disorders and abnormal coagulation activity.
Thrombotic Risk Assessment: TAT and other relevant biomarkers provide supplementary information when evaluating patients with suspected coagulation activation or thrombotic complications.
Disseminated Intravascular Coagulation (DIC) Evaluation: TAT, PIC, TM, and t-PAIC measurements may help characterize coagulation activation, fibrinolytic changes, and endothelial injury during DIC investigations.
Coagulation and Fibrinolysis Monitoring: Serial biomarker measurements can support the assessment of changes in hemostatic activity when interpreted alongside conventional coagulation tests and clinical findings.
Our laboratory thrombosis detection kits offer practical advantages for healthcare facilities requiring detailed assessment of coagulation-related molecular markers.
Multiple Pathway Assessment: Testing across coagulation activation, fibrinolysis, and endothelial injury provides complementary information beyond individual conventional coagulation measurements.
Quantitative Biomarker Detection: The assays are designed to measure specific molecular markers in human plasma, supporting objective laboratory evaluation and comparison of results over time.
Integrated Diagnostic Solutions: ZECEN's experience in immunoassay reagent development and diagnostic instrumentation supports coordinated laboratory testing workflows with appropriate compatible systems.
ZECEN combines in vitro diagnostic reagent development with immunoassay instrument manufacturing to provide specialized laboratory testing solutions. Explore our Thrombosis Test Kit collection, including TM, t-PAIC, PIC, and TAT assays, to compare detection targets, clinical applications, and reagent specifications for your laboratory.
